

**Connecticut Public Act No. 23-171 Disclosure for MONJUVI® (tafasitamab-cxix)**

**Wholesale Acquisition Cost (WAC) Information for Connecticut Prescribers and Pharmacists**

MorphoSys US Inc. provides the following information to Connecticut prescribers and pharmacists, in accordance with the requirements in Connecticut Public Act No. 23-171.

The following amount reflects the list price, or Wholesale Acquisition Cost (WAC) of MONJUVI® (tafasitamab-cxix), as reported to third-party published pricing compendia. WAC does not necessarily reflect the actual transactional price that a particular patient, provider, or payer will pay for the drug. For instance, WAC may not take into account discounts or other price concessions on the drug.

**Marketed Product WAC:**

<b>NAME OF PRODUCT</b>	<b>NDC</b>	<b>DOSAGE FORM AND STRENGTH</b>	<b>WAC</b>
MONJUVI® (tafasitamab-cxix) for injection, for intravenous use	73535-208-01	MONJUVI 200 mg single-dose vial	\$1,328.28

*\*\* There is no available information on the variation efficacy of MONJUVI® (tafasitamab-cxix) marketed to different racial and ethnic groups.*

MONJUVI® is distributed and marketed by MorphoSys US Inc. and marketed by Incyte Corporation.

MONJUVI is a registered trademark of MorphoSys AG.

Incyte is a registered trademark of Incyte Corporation.

RC-US-CORP-00137 | September 2023